Abstract
Rationale Coronavirus disease 2019 (COVID-19) leads to hospitalization and death, especially in elderly and those with comorbidities. There are evidences showing that sitagliptin and spironolactone can potentially improve the clinical outcomes of COVID-19 cases.
Objective In this observational study on acutely symptomatic outpatient COVID-19 cases, we investigated the effects of spironolactone and sitagliptin on the outcomes of the disease.
Methods This prospective cohort study was conducted at Shiraz University of Medical Sciences Clinics during the fifth wave of the COVID-19 pandemic between July 2021 and September 2021. We followed mild to moderate symptomatic COVID-19 patients, who were treated with either combination (spironolactone 100 mg daily and sitagliptin 100 mg daily) or standard (steroid, antiviral and/or supportive care) therapy up to 30 days. Our primary outcome was hospitalization rate. The secondary outcomes included ER visit, duration of disease, and complications, such as hypoglycemia, low blood pressure or altered mental status.
Results Of the 206 patients referred to clinics, 103 received standard therapy and 103 treated with combination therapy. There were no significant differences in baseline characteristics, except for slightly higher clinical score in control group (6.92 ± 4.01 control, 4.87 ± 2.92 combination; P <0.0001). Treatment with combination therapy was associated with lower admission rate (5.8% combination, 22.3% control; P = 0.0011), ER visits (7.8% combination, 23.3% control; P = 0.0021) and average duration of symptoms (6.67 ± 2.30 days combination, 18.71 ± 6.49 days control; P =<0.0001).
Conclusion In this prospective cohort study of acutely ill outpatients with COVID-19, the combination of sitagliptin and spironolactone reduced duration of COVID infection and hospital visits better than standard therapeutic approaches. The effects of combination of sitagliptin and spironolactone in COVID-19 patients should be further verified in a double blind, randomized, placebo-controlled trial.
Iranian Registry of Clinical Trials IRCT registration number: IRCT20201003048904N2, Registration date: December 10, 2020.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The trial registry used was the Iranian Registry of Clinical Trials (IRCT). The registration number is IRCT20201003048904N2. The full details of the protocol are available here: https://www.irct.ir/trial/52607
Funding Statement
Shiraz University of Medical Sciences supported this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of the University of Kentucky and the Shiraz University of Medical Sciences approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: Davarpanah{at}sums.ac.ir
Email: radatorwovor{at}uky.edu
Email: Yaas.mansouri{at}gmail.com
Email: Elhamrj96{at}gmail.com
Email: amirparsa1996{at}yahoo.com
Email: Hajiyanimehdi{at}gmail.com
Email: Hossainfaramarzi{at}yahoo.com
Email: ramakanth.kavuluru{at}uky.edu
Data Availability
The data produced in the present study are available upon reasonable request to authors.
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- ADAM17
- Disintegrin and metalloproteinase domain-containing protein 17
- COVID-19
- coronavirus disease 2019
- DPP4
- dipeptidyl peptidase-4
- ER
- emergency room
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SUMS
- Shiraz University of Medical Sciences
- TMPRSS2
- transmembrane protease serine 2
